HAART Definition:
The following is a paragraph defining HAART for the "Methods Section" of MACS publications (as of September 2010).
The definition of HAART was guided by the DHHS/Kaiser Panel [DHHS/Kaiser Nov. 2014] guidelines and defined as three or more antiretroviral (ART) drugs consisting of one or more PIs or one NNRTI or the NRTIs or an integrase inhibitor (II) or an entry inhibitor (including fusion inhibitors; EI). The percentages are based on total HIV+ person-visits with available therapy data from July 1995 to September 2014. The first paragraph may be used for papers that are related to HAART.
Specific HAART regimens consist of (a) PI-based regimens with or without NNRTI or II or EI (52%); (b) NNRTI-based regimens with or without II or EI but in the absence of PI (41%); (c) all-NRTI regimens (3%), (d) II- or EI-based regimens without PI and NNRTI (4%).
Regimens with three or more ARTs containing the following combinations are not considered HAART: two or more NNRTIs, an NNRTI with an unboosted PI (i.e.,without ritonavir (RTV) or cobicistat), unboosted atazanavir with TDF, boosted nelfinavir (NFV), etravirine with RTV boosted atazanavir or fosamprenavir or tipranavir, one boosted PI with one NRTI without other ARTs, all triple-NRTI regimens except for abacavir+ zidovudine + lamivudine or tenofovir + zidovudine + lamivudine , and two NRTI combinations - zidovudine (AZT) + stavudine (d4T) or emtricitabine (FTC) + lamivudine (3TC). In general, the three most frequent cases of combination therapy that did not meet the HAART definition were: (a) two NRTIs without other ARTs (32%); (b) unallowable combinations of NNRTI and PI (24%) and (c) unallowable unboosted PI (16%).
The most frequent case of monotherapy was one NRTI (66%). Of the other monotherapy cases, one PI accounted for 30%; and one NNRTI accounted for 3%.
Reference:
DHHS/Henry J. Kaiser Family Foundation Panel on Clinical Practices for the Treatment of HIV infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. November 2014 revision. Available at:
https://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultAndAdolescentGL.pdf.
Definitions:
HAART = highly active antiretroviral therapy
NNRTI = non-nucleoside reverse transcriptase inhibitor
NRTI = nucleoside or nucleotide reverse transcriptase inhibitor
PI = protease inhibitor
MACS Publication Policy: Key elements of publication policy/procedures
MACS full acknowledgment: All publications and presentations of studies utilizing samples and/or data supplied by the MACS should acknowledge the contribution of samples and/or data, as well as the MACS consortia. The suggested language for acknowledgment is below.
Data in this manuscript were collected by the Multicenter AIDS Cohort Study (MACS) with centers at
Baltimore (U01-AI35042): The Johns Hopkins University Bloomberg School of Public Health: Joseph B. Margolick (PI), Todd Brown (PI), Jay Bream, Adrian Dobs, Michelle Estrella, W. David Hardy, Lisette Johnson-Hill, Sean Leng, Anne Monroe, Cynthia Munro, Michael W. Plankey, Wendy Post, Ned Sacktor, Jennifer Schrack, Chloe Thio;
Chicago (U01-AI35039): Feinberg School of Medicine, Northwestern University, and Cook County Bureau of Health Services: Steven M. Wolinsky (PI), Sheila Badri, Dana Gabuzda, Frank J. Palella, Jr., Sudhir Penugonda, John P. Phair, Susheel Reddy, Matthew Stephens, Linda Teplin;
Los Angeles (U01-AI35040): University of California, UCLA Schools of Public Health and Medicine: Roger Detels (PI), Otoniel Martínez-Maza (PI), Otto Yang (Co-PI), Peter Anton, Robert Bolan, Elizabeth Breen, Anthony Butch, Shehnaz Hussain, Beth Jamieson, John Oishi, Harry Vinters, Dorothy Wiley, Mallory Witt, Stephen Young, Zuo Feng Zhang;
Pittsburgh (U01-AI35041): University of Pittsburgh, Graduate School of Public Health: Charles R. Rinaldo (PI), Lawrence A. Kingsley (PI), Jeremy J. Martinson (PI), James T. Becker, Phalguni Gupta, Kenneth Ho, Susan Koletar, John W. Mellors, Anthony J. Silvestre, Ronald D. Stall;
Data Coordinating Center (UM1-AI35043): The Johns Hopkins University Bloomberg School of Public Health: Lisa P. Jacobson (PI), Gypsyamber D’Souza (PI), Alison Abraham, Keri Althoff, Michael Collaco, Priya Duggal, Sabina Haberlen, Eithne Keelaghan, Heather McKay, Alvaro Muńoz , Derek Ng, Anne Rostich, Eric C. Seaberg, Sol Su, Pamela Surkan, Nicholas Wada.
Institute of Allergy and Infectious Diseases: Robin E. Huebner; National Cancer Institute: Geraldina Dominguez.
The MACS is funded primarily by the National Institute of Allergy and Infectious Diseases (NIAID), with additional co-funding from the National Cancer Institute (NCI), the National Institute on Drug Abuse (NIDA), and the National Institute of Mental Health (NIMH). Targeted supplemental funding for specific projects was also provided by the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute on Deafness and Communication Disorders (NIDCD). MACS data collection is also supported by UL1-TR001079 (JHU ICTR) from the National Center for Advancing Translational Sciences (NCATS) a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. The contents of this publication are solely the responsibility of the authors and do not represent the official views of the National Institutes of Health (NIH), Johns Hopkins ICTR, or NCATS. The MACS website is located at http://aidscohortstudy.org/.
- Suggested alternative acknowledgment for manuscripts when MACS data/specimens have been used: All publications and presentations of studies utilizing samples and/or data supplied by the MACS should acknowledge both the contributions of samples and the MACS collaboration itself. Where possible, the full acknowledgment (see above) should be used. For papers external to the MACS or to journals that require signatures of all in the acknowledgment, a shortened version, augmented with other investigator names (according to co-authorship) may be used:
Data in this manuscript were collected by the Multicenter AIDS Cohort Study (MACS). MACS (Principal Investigators): Johns Hopkins University Bloomberg School of Public Health (Joseph Margolick, Todd Brown), U01-AI35042; Northwestern University (Steven Wolinsky), U01-AI35039; University of California, Los Angeles (Roger Detels, Otoniel Martinez-Maza, Otto Yang), U01-AI35040; University of Pittsburgh (Charles Rinaldo, Lawrence Kingsley, Jeremy Martinson), U01-AI35041; the Center for Analysis and Management of MACS, Johns Hopkins University Bloomberg School of Public Health (Lisa Jacobson, Gypsyamber D'Souza), UM1-AI35043. The MACS is funded primarily by the National Institute of Allergy and Infectious Diseases (NIAID), with additional co-funding from the National Cancer Institute (NCI), the National Institute on Drug Abuse (NIDA), and the National Institute of Mental Health (NIMH). Targeted supplemental funding for specific projects was also provided by the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute on Deafness and Communication Disorders (NIDCD). MACS data collection is also supported by UL1-TR001079 (JHU ICTR) from the National Center for Advancing Translational Sciences (NCATS) a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. The contents of this publication are solely the responsibility of the authors and do not represent the official views of the National Institutes of Health (NIH), Johns Hopkins ICTR, or NCATS. . The MACS website is located at http://aidscohortstudy.org/.
- Additional acknowledgment to be added for all ARRA-1 manuscripts:
The research was also supported by the HIV Prevention Trials Network (HPTN) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute on Drug Abuse (NIDA), the National Institute of Mental Health (NIMH), and the Office of AIDS Research, of the National Institutes of Health (NIH), Dept. of Health and Human Services (DHHS) (UM1-AI068613)
- Additional acknowledgment to be added for all cancer related manuscripts:
Cancer incidence data were provided by the following state agencies: 1) Maryland Cancer Registry, Center for Cancer Prevention and Control, Department of Health and Mental Hygiene, Baltimore, MD 21201; 2) Illinois Department of Public Health, Illinois State Cancer Registry; 3) Bureau of Health Statistics & Research, Pennsylvania Department of Health, Harrisburg, Pennsylvania; 4) Ohio Cancer Incidence Surveillance System (OCISS), Ohio Department of Health (ODH), a cancer registry partially supported in the National Program of Cancer Registries at the Centers for Disease Control and Prevention (CDC) through Cooperative Agreement # 5U58DP000795-05; and 5) California Department of Public Health pursuant to California Health and Safety Code Section 103885; CDC’s National Program of Cancer Registries, under cooperative agreement 5NU58DP003862-04/DP003862; the National Cancer Institute's Surveillance, Epidemiology and End Results Program under contract HHSN261201000140C awarded to the Cancer Prevention Institute of California, contract HHSN261201000035C awarded to the University of Southern California, and contract HHSN261201000034C awarded to the Public Health Institute. We acknowledge the State of Maryland, the Maryland Cigarette Restitution Fund, and the National Program of Cancer Registries of the CDC for the funds that support the collection and availability of the cancer registry data. The analyses, findings, interpretations and conclusions of this report are those of the authors. No endorsement by any of the states providing data, the National Cancer Institute, the CDC or their Contractors and Subcontractors is intended nor should be inferred.
NIH Public Access Policy:
Lead authors are responsible for complying with the NIH Public Access Policy, that peer-reviewed manuscripts arising from NIH funding and ACCEPTED FOR PUBLICATION on or after April 7, 2008 are deposited in PubMed Central (PMC). Any publication using MACS data and/or specimens falls under this policy. The PMCID or NIHMSID should be sent to Judy Konig (jkonig@jhu.edu) at CAMACS along with notification of the manuscript being accepted for publication and the name of the journal.
Links to author's instructions for specific journals
